Antihypertensive Drugs Market by Drug Class (Alpha-Blockers, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers), Form (Intravenous Injections, Oral Tablets/Capsules, Transdermal Patches), Indication, Distribution Channel, End-User -

Antihypertensive Drugs Market by Drug Class (Alpha-Blockers, Angiotensin Converting Enzyme Inhibitors, Angiotensin Receptor Blockers), Form (Intravenous Injections, Oral Tablets/Capsules, Transdermal Patches), Indication, Distribution Channel, End-User - Global Forecast 2024-2030


The Antihypertensive Drugs Market size was estimated at USD 24.70 billion in 2023 and expected to reach USD 25.76 billion in 2024, at a CAGR 4.66% to reach USD 33.99 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antihypertensive Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antihypertensive Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antihypertensive Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alembic Pharmaceuticals Limited, Alkem Laboratories, Apikos Pharma, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Centurion Remedies Private Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lupin Ltd., Merck & Co., Inc., Novartis AG, Sanofi S.A., Saphnix Lifesciences, Schwitz Biotech, Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antihypertensive Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class

Alpha-Blockers
  • Angiotensin Converting Enzyme Inhibitors
  • Angiotensin Receptor Blockers
  • Beta-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Renin Inhibitors
  • Vasodilators
  • Form

    Intravenous Injections
  • Oral Tablets/Capsules
  • Transdermal Patches
  • Indication

    Primary Hypertension
  • Secondary Hypertension
  • Distribution Channel

    Offline
  • Online
  • End-User

    Home Care Facilities
  • Hospitals & Clinics
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Antihypertensive Drugs Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antihypertensive Drugs Market?
    3. What are the technology trends and regulatory frameworks in the Antihypertensive Drugs Market?
    4. What is the market share of the leading vendors in the Antihypertensive Drugs Market?
    5. Which modes and strategic moves are suitable for entering the Antihypertensive Drugs Market?


    Note: PDF & Excel + Online Access - 1 Year

  • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Antihypertensive Drugs Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Surging prevalence of hypertension, along with the growing geriatric population
    5.1.1.2. Increase in healthcare expenditure worldwide
    5.1.1.3. Growing consumer awareness of early diagnosis and treatment
    5.1.2. Restraints
    5.1.2.1. Stringent approval process and huge costs involved in drug development
    5.1.3. Opportunities
    5.1.3.1. Introduction of a new class of antihypertensive drugs
    5.1.3.2. Surge in approvals of novel drugs from regulatory bodies
    5.1.4. Challenges
    5.1.4.1. Concern regarding adverse health outcomes of antihypertensive drugs
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Antihypertensive Drugs Market, by Drug Class
    6.1. Introduction
    6.2. Alpha-Blockers
    6.3. Angiotensin Converting Enzyme Inhibitors
    6.4. Angiotensin Receptor Blockers
    6.5. Beta-Blockers
    6.6. Calcium Channel Blockers
    6.7. Diuretics
    6.8. Renin Inhibitors
    6.9. Vasodilators
    7. Antihypertensive Drugs Market, by Form
    7.1. Introduction
    7.2. Intravenous Injections
    7.3. Oral Tablets/Capsules
    7.4. Transdermal Patches
    8. Antihypertensive Drugs Market, by Indication
    8.1. Introduction
    8.2. Primary Hypertension
    8.3. Secondary Hypertension
    9. Antihypertensive Drugs Market, by Distribution Channel
    9.1. Introduction
    9.2. Offline
    9.3. Online
    10. Antihypertensive Drugs Market, by End-User
    10.1. Introduction
    10.2. Home Care Facilities
    10.3. Hospitals & Clinics
    11. Americas Antihypertensive Drugs Market
    11.1. Introduction
    11.2. Argentina
    11.3. Brazil
    11.4. Canada
    11.5. Mexico
    11.6. United States
    12. Asia-Pacific Antihypertensive Drugs Market
    12.1. Introduction
    12.2. Australia
    12.3. China
    12.4. India
    12.5. Indonesia
    12.6. Japan
    12.7. Malaysia
    12.8. Philippines
    12.9. Singapore
    12.10. South Korea
    12.11. Taiwan
    12.12. Thailand
    12.13. Vietnam
    13. Europe, Middle East & Africa Antihypertensive Drugs Market
    13.1. Introduction
    13.2. Denmark
    13.3. Egypt
    13.4. Finland
    13.5. France
    13.6. Germany
    13.7. Israel
    13.8. Italy
    13.9. Netherlands
    13.10. Nigeria
    13.11. Norway
    13.12. Poland
    13.13. Qatar
    13.14. Russia
    13.15. Saudi Arabia
    13.16. South Africa
    13.17. Spain
    13.18. Sweden
    13.19. Switzerland
    13.20. Turkey
    13.21. United Arab Emirates
    13.22. United Kingdom
    14. Competitive Landscape
    14.1. FPNV Positioning Matrix
    14.2. Market Share Analysis, By Key Player
    14.3. Competitive Scenario Analysis, By Key Player
    15. Competitive Portfolio
    15.1. Key Company Profiles
    15.1.1. Abbott Laboratories
    15.1.2. Alembic Pharmaceuticals Limited
    15.1.3. Alkem Laboratories
    15.1.4. Apikos Pharma
    15.1.5. AstraZeneca PLC
    15.1.6. Bayer AG
    15.1.7. Boehringer Ingelheim International GmbH
    15.1.8. Centurion Remedies Private Limited
    15.1.9. Daiichi Sankyo Co., Ltd.
    15.1.10. Dr. Reddy's Laboratories
    15.1.11. F. Hoffmann-La Roche AG
    15.1.12. Gilead Sciences, Inc.
    15.1.13. Glenmark Pharmaceuticals Ltd.
    15.1.14. Johnson & Johnson Services, Inc.
    15.1.15. Lupin Ltd.
    15.1.16. Merck & Co., Inc.
    15.1.17. Novartis AG
    15.1.18. Sanofi S.A.
    15.1.19. Saphnix Lifesciences
    15.1.20. Schwitz Biotech
    15.1.21. Sun Pharmaceutical Industries Limited
    15.1.22. Takeda Pharmaceutical Company Limited
    15.1.23. Teva Pharmaceutical Industries Ltd.
    15.1.24. United Therapeutics Corporation
    15.1.25. Zydus Lifesciences Limited
    15.2. Key Product Portfolio
    16. Appendix
    16.1. Discussion Guide
    16.2. License & Pricing
    FIGURE 1. ANTIHYPERTENSIVE DRUGS MARKET RESEARCH PROCESS
    FIGURE 2. ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ANTIHYPERTENSIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ANTIHYPERTENSIVE DRUGS MARKET DYNAMICS
    FIGURE 7. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
    FIGURE 8. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2030 (%)
    FIGURE 10. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
    FIGURE 12. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
    FIGURE 14. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
    FIGURE 16. ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. AMERICAS ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 20. UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 22. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 25. ANTIHYPERTENSIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 26. ANTIHYPERTENSIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2023

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings